Paradigm Biopharmaceuticals scores A$16m investment—Here’s what it means for osteoarthritis treatment
Paradigm Biopharmaceuticals Ltd. (ASX: PAR) has secured a significant A$16 million in funding, positioning the company to launch its pivotal Phase 3 global clinical trial ... Read More